Cyclodextrin-based polymers for therapeutic delivery

-3. (canceled)

-20. (canceled)

A method of treating cancer in a subject, the method comprising administering a CDP-taxane conjugate, wherein the CDP-taxane conjugate has the following formula:

• wherein each L is independently a linker or absent, each D is independently a taxane or —OH, each comonomer comprises polyethylene glycol (PEG), and n is at least 4, provided that the CDP-taxane conjugate comprises at least one taxane selected from docetaxel, larotaxel, and cabazitaxel, to a subject in an amount effective to treat the cancer, to thereby treat the cancer.

(canceled)

-25. (canceled)

A method of treating metastatic or locally advanced breast cancer in a subject, the method comprising providing a subject who has metastatic or locally advanced breast cancer and has been treated with a chemotherapeutic agent which did not effectively treat the cancer or which had an unacceptable side effect, and

• administering a CDP-taxane conjugate to a subject in an amount effective to treat the cancer, to thereby treat the cancer.

-36. (canceled)

A method of treating hormone refractory prostate cancer in a subject, the method comprising:

• providing a subject who has hormone refractory prostate cancer and has been treated with a chemotherapeutic agent that did not effectively treat the cancer or who had an unacceptable side effect, and
• administering a CDP-taxane conjugate to a subject in an amount effective to treat the cancer, to thereby treat the cancer.

-54. (canceled)

-137. (canceled)

A method of treating a subject having cancer, the method comprising selecting a subject having cancer who has received an anticancer agent and has a neutrophil count less than a standard;

• and
• administering a CDP-taxane conjugate to the subject in an amount effective to treat the cancer, to thereby treat the cancer.

-146. (canceled)

A method for treating a subject having cancer, the method comprising:

• selecting a subject with cancer who has moderate to severe neutropenia;
• and
• administering a CDP-taxane conjugate to the subject in an amount effective to treat the cancer, to thereby treat the cancer.

-157. (canceled)

A method for treating a subject having cancer, the method comprising:

• selecting a subject with cancer who has experienced one or more symptom of neuropathy from treatment with a anticancer agent;
• and
• administering a CDP-taxane conjugate, to the subject in an amount effective to treat the cancer, to thereby treat the cancer.

-181. (canceled)

A method of treating a subject having cancer, the method comprising:

• selecting a subject with cancer who has or is at risk of having hepatic impairment, e.g., a subject having alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) levels greater than 1.5 times the upper limit of normal (ULN) and/or bilirubin levels greater than 2 times the ULN;
• and
• administering a CDP-taxane conjugate to the subject in an amount effective to treat the cancer, to thereby treat the cancer.

-191. (canceled)

A method of treating a subject having cancer, the method comprising:

• selecting a subject having cancer who is currently being administered or will be, administered a cytochrome P450 isoenzyme, and/or a CYP2C8 inhibitor;
• and
• administering a CDP-taxane conjugate to the subject at a dose described herein, to thereby treat the cancer.

-197. (canceled)

A method of selecting a subject having cancer, for treatment with a CDP-taxane conjugate, the method comprising:

• determining if a subject with cancer is at risk for or has diarrhea or has experienced diarrhea from treatment with an anticancer agent, and
• selecting a subject who is at risk for or has diarrhea or has experienced diarrhea from treatment with an anticancer agent for treatment with a CDP-taxane conjugate.

(canceled)

A CDP-taxane conjugate having the following formula:

• wherein each L is independently a linker or absent, each D is independently a taxane or —OH, each comonomer comprises polyethylene glycol (PEG), provided that the CDP-taxane conjugate comprises at least one taxane selected from docetaxel, larotaxel, and cabazitaxel.

-209. (canceled)